SVRA: Savara Inc Stock Price, Quote and News

The 2 analysts offering price forecasts for Savara have a median target of 2.50, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a 68.80 difference from the last price of 1.72. The 0.10% of Savara Inc.’s shares are in the hands of company insiders while institutional holders own 70.50% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.52 million on Jan 12, 2023, giving us a short ratio of 4.5.

In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.

• Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price.
• It attempts to reflect the cash profit generated by a company’s operations.
• The median estimate represents a 68.80 difference from the last price of 1.72.
• © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Only 1 people have added Savara to their MarketBeat watchlist in the last 30 days.

Savara Inc. Announces Management Changes

All investments involve risk, and not all risks are suitable for every investor. The value of securities may fluctuate and as a result, clients may lose more than their original investment. The past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss in a down market. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Apex Crypto is not a registered broker-dealer or FINRA member and your cryptocurrency holdings are not FDIC or SIPC insured. Please ensure that you fully understand the risks involved before trading. Not all coins provided by Apex Crypto LLC are available to New York residents. Please visit /cryptocurrency to see a list of crypto available to trade. The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

SVRA

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. One share of SVRA stock can currently be purchased for approximately $1.82. Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat’s FREE daily newsletter.

Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Shares of Savara Inc. tumbled 48% in premarket trade Wednesday, after the orphan lung disease company said the U.S.

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. The firm’s lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune… Savara’s market cap is calculated by multiplying SVRA’s current stock price of $1.72 by SVRA’s total outstanding shares of 114,064,736.

News and Social Media Coverage

Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.

The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission . Webull Financial LLC is a member of the Financial Industry Regulatory Authority , Securities Investor Protection Corporation , The New York Stock Exchange , NASDAQ and Cboe EDGX Exchange, Inc . Realtime quote and/or trades are not sourced from all markets. Bloomberg Wealth with David Rubenstein Renowned financier, Co-Founder of The Carlyle Group, and philanthropist David Rubenstein provides unparalleled access to the world’s most successful investors. In one-on-one interviews, Rubenstein will learn investing strategies and tactics from some of the world’s top wealth creators.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

Based on 5 analysts giving stock ratings to SVRA in the past 3 months. Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases.

The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

Industry Products

Live from Hong Kong, bringing you the most important global how to drain a swollen brain and breaking markets news information as it happens. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. 52 week high is the highest price of a stock in the past 52 weeks, or one year. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyondspring (BYSI – Research Report) and Savara (SVRA – Research Report) with bullish sentiments. Savara , LGL Group and Harte Hanks have been selected as the breakout stocks for today.

It’s https://1investing.in/ by multiplying the current market price by the total number of shares outstanding. Wainwright maintained a Buy rating on Savara (SVRA – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $1.13, close to its 52-week … The chart below shows how a company’s share price and consensus price target have changed over time.

Based on an average trading volume of 242,400 shares, the days-to-cover ratio is presently 4.0 days. Approximately 1.4% of the company’s shares are sold short. Market cap, also known as market capitalization, is the total market value of a company.

You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Past performance is not indicative of future performance.